Table 1.

Study Eligibility Criteria.

Inclusion Criteria

Exclusion Criteria

≥18 years old Confirmation of glenohumeral OA on imaging ≥5/10 VAS pain as a result of primary or secondary glenohumeral OA ≥3 months of pain after onset of symptoms that has failed conservative treatments (e.g., medications, physical therapy) Transient relief of symptoms (≥50% relief) after an ultrasound-guided diagnostic intra-articular injection containing local anesthetic into the glenohumeral joint

Non-English-speaking or illiterate Presence of painful, concurrent cervical spine conditions Current NSAID use Current or recent use of Coumadin or similar anticoagulants (e.g., dabigatran) Known coagulopathy or bleeding dyscrasia Platelet count <150,000/mm3 Allergic reaction to poultry or previous viscosupplementation Involvement in worker’s compensation or active litigation involving the affect shoulder Inability to refrain from NSAID use for 5 days prior to and 6 weeks after the injection Corticosteroid injection to the affecteds shoulder within the last 3 months Viscosupplementation or PRP injection to the affected shoulder within the last 6 months Presence of acute fracture History of shoulder tumor Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/inflammatory disease [e.g., gout], active infection) Presence of functionally limiting psychiatric and somatoform disorders

HIV: human immunodeficiency virus; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis; PRP: platelet-rich plasma